Logo image of GNTA

GENENTA SCIENCE SPA - ADR (GNTA) Stock Fundamental Analysis

NASDAQ:GNTA - Nasdaq - US36870W1009 - ADR - Currency: USD

3.49  -0.22 (-5.95%)

Fundamental Rating

3

Overall GNTA gets a fundamental rating of 3 out of 10. We evaluated GNTA against 550 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for GNTA as it has an excellent financial health rating, but there are worries on the profitability. GNTA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year GNTA has reported negative net income.
GNTA had a negative operating cash flow in the past year.
GNTA had negative earnings in each of the past 5 years.
GNTA had a negative operating cash flow in each of the past 5 years.
GNTA Yearly Net Income VS EBIT VS OCF VS FCFGNTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

GNTA has a Return On Assets of -60.12%. This is comparable to the rest of the industry: GNTA outperforms 40.91% of its industry peers.
Looking at the Return On Equity, with a value of -71.32%, GNTA is in line with its industry, outperforming 53.82% of the companies in the same industry.
Industry RankSector Rank
ROA -60.12%
ROE -71.32%
ROIC N/A
ROA(3y)-45.86%
ROA(5y)-36.67%
ROE(3y)-51.85%
ROE(5y)-41.34%
ROIC(3y)N/A
ROIC(5y)N/A
GNTA Yearly ROA, ROE, ROICGNTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for GNTA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
GNTA Yearly Profit, Operating, Gross MarginsGNTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, GNTA has more shares outstanding
The number of shares outstanding for GNTA has been increased compared to 5 years ago.
GNTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
GNTA Yearly Shares OutstandingGNTA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M
GNTA Yearly Total Debt VS Total AssetsGNTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2.2 Solvency

GNTA has an Altman-Z score of 7.69. This indicates that GNTA is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of GNTA (7.69) is better than 83.82% of its industry peers.
GNTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 7.69
ROIC/WACCN/A
WACCN/A
GNTA Yearly LT Debt VS Equity VS FCFGNTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 10M -10M 20M 30M

2.3 Liquidity

GNTA has a Current Ratio of 6.89. This indicates that GNTA is financially healthy and has no problem in meeting its short term obligations.
GNTA has a Current ratio of 6.89. This is in the better half of the industry: GNTA outperforms 66.36% of its industry peers.
GNTA has a Quick Ratio of 6.89. This indicates that GNTA is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 6.89, GNTA is doing good in the industry, outperforming 66.73% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.89
Quick Ratio 6.89
GNTA Yearly Current Assets VS Current LiabilitesGNTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

0

3. Growth

3.1 Past

GNTA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 23.70%, which is quite impressive.
EPS 1Y (TTM)23.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0.63%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -3.77% on average over the next years.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-9.23%
EPS Next 2Y-3.77%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GNTA Yearly EPS VS EstimatesGNTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 -0.2 -0.4 -0.6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GNTA. In the last year negative earnings were reported.
Also next year GNTA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GNTA Price Earnings VS Forward Price EarningsGNTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GNTA Per share dataGNTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5

4.3 Compensation for Growth

A cheap valuation may be justified as GNTA's earnings are expected to decrease with -3.77% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.77%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

GNTA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

GENENTA SCIENCE SPA - ADR

NASDAQ:GNTA (8/11/2025, 8:00:01 PM)

3.49

-0.22 (-5.95%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners10.37%
Inst Owner Change0.09%
Ins Owners27.5%
Ins Owner ChangeN/A
Market Cap63.83M
Analysts82.86
Price Target21.42 (513.75%)
Short Float %0.06%
Short Ratio0.44
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-8.7%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.4
P/tB 4.4
EV/EBITDA N/A
EPS(TTM)-0.57
EYN/A
EPS(NY)-0.84
Fwd EYN/A
FCF(TTM)-0.4
FCFYN/A
OCF(TTM)-0.4
OCFYN/A
SpS0
BVpS0.79
TBVpS0.79
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -60.12%
ROE -71.32%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-45.86%
ROA(5y)-36.67%
ROE(3y)-51.85%
ROE(5y)-41.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.11%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.89
Quick Ratio 6.89
Altman-Z 7.69
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)114.19%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)23.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0.63%
EPS Next Y-9.23%
EPS Next 2Y-3.77%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y16.78%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-141.01%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y44.34%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.31%
OCF growth 3YN/A
OCF growth 5YN/A